Cytosorbents Corporation  (CTSO)
Other Ticker:  
Price: $1.0100 $0.00 0.000%
Day's High: $1.01 Week Perf: 1 %
Day's Low: $ 0.95 30 Day Perf: 1.5 %
Volume (M): 96 52 Wk High: $ 4.29
Volume (M$): $ 97 52 Wk Avg: $2.40
Open: $0.99 52 Wk Low: $0.84

 Market Capitalization (Millions $) 45
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) 37
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 1

Cytosorbents Corporation
Cytosorbents Corporation is a medical device company that specializes in blood purification technology. The company's flagship product, Cytosorb, is designed to remove harmful substances from the bloodstream, such as cytokines, toxins, and excessive fluids, in critically ill patients. The technology behind Cytosorb involves the use of highly porous polymer beads that adsorb these substances, helping to alleviate inflammation and organ dysfunction. Cytosorbents Corporation aims to improve patient outcomes and reduce the impact of severe conditions like sepsis, acute respiratory distress syndrome, and other life-threatening conditions.

   Company Address: 305 College Road East Princeton, 8540 NJ
   Company Phone Number: 329-8885   Stock Exchange / Ticker: NASDAQ CTSO
   CTSO is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Revolutionizing Heart Transplants: Excellent Clinical Outcomes Achieved through CytoSorb Blood Purification, Diminishing Organ Failure Risks

Published Wed, Jan 17 2024 12:15 PM UTC

This innovative technology, designed and patented by CytoSorbents Corporation, focuses on reducing the risk factors linked with organ failure and dysfunction following a heart transplant. These risk factors include a high inflammatory state, potential damage caused by ischemia and reperfusion injury, and complications due to the transplantation procedure itself.The primary ...

Clinical Study

CytoSorb?: Illuminating Hope in Sep. Shock - Unleashing the Power of Hemoadsorption

Published Thu, Dec 28 2023 12:00 PM UTC

Septic shock remains a significant healthcare burden worldwide, with high mortality rates and limited treatment options. The recent advancements in hemoadsorption therapy using the CytoSorb? extracorporeal hemoperfusion device have shown promising results in improving patient outcomes. This article presents an extensive review of two pivotal studies, namely CytoSorbents Prov...

Financing Agreement

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering, Bolstering Balance Sheet and Attracting Insider Investments

Published Wed, Dec 13 2023 2:15 PM UTC

CytoSorbents Strengthens Balance Sheet with $10.3M Registered Direct Offering. Insiders invest $435,000 Despite Long-Term Borrowings
CytoSorbents Corporation, a leading critical care immunotherapy company specializing in blood purification, has successfully completed a $10.3 million registered direct offering. The company was able to strengthen its balance sheet thr...

Cytosorbents Corporation

Cytosorbents Corporation Achieves Modest Growth, Reflecting Stability in Financial Performance by September 2023

Cytosorbents Corporation (CTSO), a leading player in the Medical Equipment & Supplies sector, recently released their financial results for the fiscal interval ending September 30, 2023. The report reveals a mixed bag of results, with some encouraging signs of improvement, but also areas of concern. Let's delve into the facts and ponder how they might shape the company's future.
Positive Trends in Earnings:
CTSO showcased a noteworthy improvement in earnings per share (EPS) compared to the previous year. The company experienced a loss of $-0.21 per share, seeing a significant reduction from $-0.28 in the corresponding period last year. Additionally, the company successfully managed to narrow down its deficit from $-0.14 per share in the previous reporting period. These positive trends indicate that CTSO's efforts to streamline operations and drive efficiency are starting to pay off.

Cytosorbents Corporation

Medical Equipment & Supplies Giant, Cytosorbents Corporation, Reverses Deficit Trend Amid Sector Struggles: Reports Strong Growth for Fiscal Q2 2023!

Cytosorbents Corporation, a prominent Medical Equipment & Supplies company, showcased remarkable financial performance in the second quarter of 2023. While many competitors struggled with declining orders and revenue retraction, Cytosorbents Corporation's results revealed significant improvements. This article aims to analyze the company's financial results and explore how these achievements are likely to impact its future prospects.
1. Decrease in Loss per Share:
One noteworthy aspect of Cytosorbents Corporation's financial results is the decrease in loss per share. The company reported a loss per share of $-0.14 for the fiscal period closing June 30, 2023, compared to $-0.25 in the previous year. This reduction signifies the company's progress in managing its expenses and optimizing operational efficiency.


Cytosorbents's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com